Brief: Actinium Pharmaceuticals Announces First Patient Treated In Third And Final Dose Cohort Of Actimab-A Clag-M Combination Phase 1 Trial In Acute Myeloid Leukemia
05/03/2020 12:32
March 5 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS ANNOUNCES FIRST PATIENT TREATED
IN
THIRD AND FINAL DOSE COHORT OF ACTIMAB-A CLAG-M COMBINATION
PHASE 1 TRIAL IN ACUTE MYELOID LEUKEMIA
* ACTINIUM PHARMACEUTICALS INC - ACTINIUM EXPECTS THIRD
COHORT TO
BE COMPLETED MID-2020.
Source text for Eikon: ID:nPnc0VKLha
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities